Introduction
Chronic obstructive pulmonary disease (COPD) is a serious
public health problem worldwide. The prevalence, morbidity,
and mortality are expected to rise, especially in countries with
a rapidly aging population and even in populations with reduced smoking rates. A study published by the World
Bank/World Health Organization reported that COPD is
likely to rise from being the twelfth most burdensome disease
in 1990 to the fifth in 2020. This will place an enormous
burden on the healthcare system and will cause a loss in health related quality of life (HRQoL) for many patients with COPD. Treatment for COPD is often primarily aimed at improving airflow obstruction by bronchodilator and anti-inflammatory therapy, despite indications that airflow obstruction is irreversible and there is an apparent lack of effect of pharmacological interventions on the progressive decline in health status. Despite optimal pharmacological treatment, many patients with COPD experience substantial functional impairment. However, airflow obstruction correlates poorly with disease perception by the patient. COPD is a systemic inflammatory disease and, besides airflow limitation and hyperinflation due to loss of elastic recoil and intrinsic airway narrowing, systemic deficits such as skeletal and respiratory muscle dysfunction are prominent features. There is a growing need for other forms of treatment for COPD patients, not only to control and alleviate symptoms and complications of respiratory dysfunction but also to teach them how to carry out the activities of daily living optimally in the face of their physiological impairment.
แนะนำโรคระบบทางเดินหายใจเรื้อรังอุปสรรค (แอนเดอรส์) เป็นการร้ายแรงปัญหาสาธารณสุขทั่วโลก ความชุก morbidityและคาดว่าจะเพิ่มขึ้น โดยเฉพาะอย่างยิ่งในประเทศที่มีการตายการคำนวณอายุประชากรอย่างรวดเร็ว และแม้กระทั่งในกลุ่มประชากรที่มีอัตราการสูบบุหรี่ลดลง การศึกษาที่เผยแพร่ โดยโลกองค์การอนามัยโลก/ธนาคารรายงานว่า แอนเดอรส์แนวโน้มที่จะเพิ่มขึ้นจาก ทวาทศีโรคที่เป็นภาระมากที่สุดในปี 1990 การที่ห้า 2020 นี้จะทำเป็นอย่างมากburden on the healthcare system and will cause a loss in health related quality of life (HRQoL) for many patients with COPD. Treatment for COPD is often primarily aimed at improving airflow obstruction by bronchodilator and anti-inflammatory therapy, despite indications that airflow obstruction is irreversible and there is an apparent lack of effect of pharmacological interventions on the progressive decline in health status. Despite optimal pharmacological treatment, many patients with COPD experience substantial functional impairment. However, airflow obstruction correlates poorly with disease perception by the patient. COPD is a systemic inflammatory disease and, besides airflow limitation and hyperinflation due to loss of elastic recoil and intrinsic airway narrowing, systemic deficits such as skeletal and respiratory muscle dysfunction are prominent features. There is a growing need for other forms of treatment for COPD patients, not only to control and alleviate symptoms and complications of respiratory dysfunction but also to teach them how to carry out the activities of daily living optimally in the face of their physiological impairment.
การแปล กรุณารอสักครู่..